To include your compound in the COVID-19 Resource Center, submit it here.

De-risking first in class

A novel cancer target in validated pathway attracted VCs to Cleave's syndicate

Cleave Biosciences Inc. has steered clear of non-dilutive partnership dollars in hopes of internally validating the profile of its first-in-class cancer therapeutic CB-5083. Now, the biotech has attracted a cadre of new investors in last

Read the full 351 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE